Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Neurosterix completed Phase 1 studies of NTX-253, an M4 positive allosteric modulator being developed for schizophrenia, and plans to advance it into Phase 2. Addex, which spun out Neurosterix in April 2024, retains a 20% equity interest; the Phase 1 study provided safety and pharmacokinetic data, but no efficacy results were reported.

Analysis

Investment read-through: modestly positive for ADXN’s pipeline optionality, but not yet a fundamental earnings event. The relevant asset sits in private Neurosterix, so Addex’s 20% interest is an indirect, illiquid claim—not near-term product revenue. Its value depends on Neurosterix’s financing terms, fully diluted ownership, and any milestone, royalty, or other economic rights; verify these before assigning material value. No Phase 1 results were disclosed, so progression to Phase 2 is a development decision, not evidence of efficacy or a de-risked safety profile.

Over days, the announcement may attract speculative interest, but the absence of numerical safety, PK, or exposure data limits what can be underwritten. Over 1–3 months, watch for the Phase 2 protocol, start timing, enrollment, and funding arrangements. Over 6–18 months, patient data—not the Phase 1 completion itself—will determine whether M4 modulation adds credible differentiation in schizophrenia. M4 approaches could benefit from broader validation of nontraditional antipsychotic mechanisms, while clinical tolerability, efficacy, and commercial differentiation remain unproven here.

The contrarian point: investors may capitalize the 20% stake too generously as if it were a liquid, attributable pipeline asset. Conversely, if Neurosterix funds Phase 2 without diluting Addex materially and reports informative patient data, the stake could be underappreciated. No defensible valuation or price target is possible without stake economics, current cap table, and trial data.

Key Decisions for Investors

• Do not chase ADXN solely on this announcement; treat it as a small, speculative increase in pipeline optionality rather than a change to near-term cash-flow expectations.
• Keep ADXN on a catalyst watchlist. Reassess when Neurosterix discloses Phase 2 design, funding, and Addex’s precise economic rights and fully diluted ownership.
• Require numerical Phase 1 safety/PK results and subsequent patient efficacy data before upgrading the thesis; a delay, adverse tolerability signal, or material dilution would weaken the value of Addex’s interest.
• No pair or options trade is warranted from the disclosed information alone; liquidity, valuation, financing terms, and the market’s initial response are not provided.